10种ABC转运蛋白在鼻咽癌顺铂耐药细胞系中的表达

Expression of Ten ABC Transporters in Cisplatin-resistant Nasopharyngeal Carcinoma Cell Lines

为研究鼻咽癌细胞CNE2中顺铂耐药与10种ABC转运蛋白的关系,分别用顺铂、顺铂+5-氟脲嘧啶来诱导CNE2耐药,在脱药培养2个月后通过MTT法测定细胞的生长曲线及其与顺铂的量效关系和耐药指数,同时,通过荧光定量PCR法检测耐药细胞与敏感细胞中10种ABC转运蛋白mRNA表达的差异,并通过免疫细胞化学法验证.MTT法结果提示,成功诱导出两株分别对顺铂、顺铂+5-氟脲嘧啶耐药的细胞株(分别命名为CNE2/DDP、CNE2/DDP+5Fu),耐药指数分别为2.58和5.31,ABCC2在两株耐药细胞株中表达均上调,分别为2.50和4.08倍,免疫细胞化学法结果表明,ABCC2在两株耐药细胞中表达均增强,同时ABCC2还可在CNE2/DDP+5Fu细胞核中表达.上述结果表明ABCC2在CNE2细胞对顺铂的耐药性中可能发挥着重要的作用.

Ten ATP binding cassette （ABC） transporters are confirmed to be associated with resistance against anticancer drugs. To investigate the relationship between these ten ABC transporters and the nasopharyngeal carcinoma cell line CNE2 resistant to cisplatin, cisplatin and cisplatin with 5-fluorouracil were used to induce the CNE2 cell to acquire the drug-resistance for I year. After these cells were cultured without drugs for 2 months, the MTT assay method was used to determine the dose-effect relationship of cisplatin and resistant index. Quantitative real time polymerase chain reaction was used to detect the mRNA expression of ten ABC transporters in CNE2 and the drug-resistant CNE2 cells, and the result was confirmed by immunocytochemical method. The results of MTT method showed that two cell lines resistant to cisplatin （named as CNE2/DDP） and cisplatin with 5-fluorouracil （named as CNE2/DDP＋5Fu） were established, with resistant index 2.58 and 5.31, respectively. Of ten ABC transporters, only ABCC2 was found to be up-regulated both in CNE2/DDP and CNE2/DDP＋5Fu cells, for increasing about 2.50 and 4.08 folds, respectively. The results of immunocytochemical method also confirmed that the expression of ABCC2 in CNE2/DDP and CNE2/DDP ＋5Fu cells were stronger that that in CNE2 cell. Furthermore, ABCC2 protein was found to be located at nuclear membrane of CNE2/DDP ＋5Fu cell but not at nuclear membrane of CNE2 cell. The results suggest that ABCC2 may play an important role in cisplatin- resistance ofnasopharyngeal carcinoma cell line CNE2.